

ESMO ADVANCED COURSE PROGRAMME

ADVANCED BREAST CANCER: FILLING THE GAPS FOLLOWING PROGRESSION ON CDK4/6 IN HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ABC

Doha, Qatar
16 November 2024

CO-CHAIRS Nadia Harbeck, Germany
Salha Bujassoum, Qatar

SPEAKERS Alessandra Gennari, Italy
Rupert Bartsch, Austria
Valentina Guarneri, Italy
Frédérique Penault-Llorca, France
Joana Ribeiro, Portugal

MODERATORS Abdulwahhab Altourah, Kuwait
Ahmed Alfaraj, Saudi Arabia
Esam Murshid, Saudi Arabia
Aydah Alawadhi, United Arab Emirates
Francois Calaud, Qatar
Abdullah Altwairgi, Saudi Arabia

LEARNING OBJECTIVES

- Understanding the function and biology of CDK4/6 in breast cancer
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4/6 inhibition in breast cancer, both in the early and metastatic setting
- Assessing the clinical and genomic features for risk of relapse in early HR+/HER2 negative breast cancer
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4/6 inhibition
- Discussing clinical cancer cases to integrate use of CDK4/6 inhibitors in clinical practice

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Stemline
A Menarini Group Company

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org | www.esmo.org



Saturday, 16 November 2024

- 09:00-09:10 **Welcome and introduction**
Salha Bujassoum, QT and Nadia Harbeck, DE
- 09:10-09:45 **Session 1 – Epidemiology of Breast Cancer in the Gulf Region**
Moderators: Abdulwahhab Altourah, KW and Francois Calaud, QT
- 20' Salha Bujassoum, QT
- 15' Discussion
- 09:45-11:15 **Session 2 – CDK4-6 inhibitors in EBC and MBC**
Moderators: Abdulwahhab Altourah, KW and Francois Calaud, QT
- 30' EBC
Nadia Harbeck, DE
- 30' MBC
Salha Bujassoum, QT
- 25' Discussion
- 11:15-11:45 Coffee Break**
- 11:45-13:45 **Session 3 – What to do after CDK4-6 inhibition in advanced breast cancer**
Moderators: Abdullah Altwairgi, SA and Esam Murshid, SA
- 20' Clinically relevant biomarkers (PI3KCA, ESR1, AKT pathway, liquid biopsy, NGS, gBRCA)
Frédérique Penault-Llorca, FR
- 20' CDK4/6 beyond progression and other endocrine based strategies
Valentina Guarneri, IT
- 20' PI3K inhibitors
Joana Ribeiro, PT
- 30' Oral SERDs
Rupert Bartsch, AT
- 30' Discussion
- 13:45-14:45 Lunch break**
- 14:45-16:05 **Session 4 – Treatment strategies**
Moderators: Abdullah Altwairgi, SA and Esam Murshid, SA
- 20' Management of endocrine sensitive disease
Alessandra Gennari, IT

20' Management of endocrine resistant disease
Nadia Harbeck, DE

20' The potential future for oral SERDs “ongoing clinical trials for oral SERDs” in early & metastatic setting
Rupert Bartsch, AT

20' Discussion

16:05-16:40 **Clinical Practice Session – Side effect management**

Moderators: Ahmed Alfaraj, SA and Aydah Alawadhi, AE

20' Management of adverse events of new endocrine-based therapies in metastatic breast cancer: Balancing efficacy and toxicity
Alessandra Gennari, IT

15' Discussion

16:40-17:00 Coffee Break

17:00-17:40 **Workshop Session**

Workshop Molecular Tumour Board HR+ MBC

Moderators: Ahmed Alfaraj, SA and Aydah Alawadhi, AE

30' Presentation of 3 cases by speaker and discussion

10' Discussion

1Case: 1st Endocrine resistant PIK3CA mutation – Alessandra Gennari, IT

2Case: 2nd line ESR1 mutation – Valentina Guarneri, IT

3Case: gBRCA mutation – Joana Ribeiro, PT

17:40-17:50 **Synthesis and wrap-up**